Cadrenal Therapeutics (CVKD) – Daily Chart (Finviz Snapshot)
Price (late Jan 2026)
$7.26
Market Cap
$17.0M
52W High
$22.90
52W Low
$6.42
Shares Out
~2.06M
Avg Analyst Target
$35.67
Static daily chart from Finviz and price/market data as of late January 2026.
NASDAQ: CVKD
Cadrenal Therapeutics – Deep Dive Analysis
Anticoagulation platform with three clinical assets (VKA, Factor XIa, 12-LOX) targeting a global market that various market research reports estimate in the 38–40 billion dollar range. | Last Updated: January 25, 2026
Lead Asset
Phase 3 Ready
Tecarfarin – Novel VKA for LVAD & ESKD
Phase 3-ready oral vitamin K antagonist designed to overcome warfarin’s limitations, especially in complex cardiorenal patients. Collaboration with Abbott for the pivotal LVAD program. Orphan Drug and Fast Track designations secured in key indications.
December 2025 Acquisition
Phase 2
VLX-1005 – First-in-Class 12-LOX Inhibitor
Acquired from Veralox Therapeutics for heparin-induced thrombocytopenia (HIT). First and only selective 12-LOX inhibitor in clinical testing. Orphan Drug and Fast Track from FDA and Orphan Drug status from EMA.
September 2025 Acquisition
Phase 2 Ready
Frunexian – IV Factor XIa Inhibitor
Acquired from eXIthera Pharmaceuticals for acute-care settings. The only Factor XIa inhibitor in development as an IV formulation for hospital procedures and device-related thrombosis. China rights retained by Sichuan Haisco after Phase 1.
Note: Cadrenal is currently the only company combining a novel VKA, Factor XIa inhibitors (IV and oral) and a 12-LOX inhibitor in a single portfolio, covering chronic, acute and immune-mediated anticoagulation niches.
1. Company Overview
From single-asset microcap to multi-pillar anticoagulation platform.
Cadrenal Therapeutics (NASDAQ: CVKD) is a clinical-stage biopharma headquartered in Ponte Vedra, Florida, focused on anticoagulation solutions for high-risk patients who are poorly served by current therapies. The company was formed in 2022 around tecarfarin and, through two 2025 acquisitions, has expanded into a broader platform combining VKA, Factor XIa and 12-LOX mechanisms.
The strategic focus is deliberately narrow: LVAD patients, end-stage kidney disease (ESKD) patients with atrial fibrillation, and patients with heparin-induced thrombocytopenia. These are difficult populations where standard oral anticoagulants (DOACs) are contraindicated or ineffective and where warfarin often fails to maintain acceptable time in therapeutic range. Rather than competing in the crowded mainstream AFib market, Cadrenal is trying to own these specialized “white space” niches with orphan-style positioning and targeted trials.
Headquarters
Ponte Vedra, FL
Founded
2022
CEO
Quang X. Pham
Clinical Assets
3 active
Cash (Q3 2025)
$3.9M
Target Market
≈$38–40B
2. The Anticoagulation Problem
Where warfarin fails and DOACs cannot be used.
Warfarin has been a mainstay for more than 60 years, but its limitations are well known: narrow therapeutic window, complex CYP450 metabolism, extensive drug and food interactions and constant INR monitoring. In complex patient populations like LVAD or ESKD, real-world studies show time in therapeutic range (TTR) often in the 37–46% range, far from ideal.
LVAD Patients (≈25,000 in the US)
Patients with left ventricular assist devices require continuous anticoagulation to prevent pump thrombosis. At the same time, they are at high risk of life-threatening bleeding. Hospitalization for a major bleed is extremely costly, and the clinical impact is severe. DOACs are generally not recommended in this setting, leaving warfarin as the default despite its instability.
ESKD + AFib Patients (hundreds of thousands in the US)
Patients with advanced kidney failure and atrial fibrillation are another difficult group. Most DOAC labels include restrictions or contraindications in severe renal impairment. Warfarin metabolism is erratic in these patients and managing INR becomes even more challenging, with higher rates of both thrombotic and bleeding events.
Heparin-Induced Thrombocytopenia (HIT)
HIT is an immune-mediated reaction to heparin that paradoxically causes thrombosis in the setting of low platelets. Tens of thousands of confirmed HIT cases are estimated annually in the US alone. Current agents (such as argatroban or bivalirudin) are direct anticoagulants and do not target the underlying immune mechanism driving platelet activation and inflammation.
Why This Matters for Cadrenal
Large pharmaceutical companies have largely prioritized broader AFib and venous thromboembolism markets, leaving smaller, technically challenging populations relatively unattended. Cadrenal is attempting to build a focused franchise where:
- Patients have limited or no effective alternatives
- Orphan Drug status can provide market exclusivity
- Regulators may accept smaller, focused trials
- Pricing power is more defensible than in crowded markets
The strategic idea is to control narrow but important niches in anticoagulation, rather than being another small player competing head-on with large DOAC franchises.
3. Pipeline Overview
Three clinical-stage assets, one IND-ready candidate and a clear thematic focus.
| Drug Candidate | Mechanism | Indication | Stage | Key Designations / Notes |
|---|---|---|---|---|
| Tecarfarin | Oral VKA (CES2 metabolism) | LVAD, ESKD + AFib | Phase 3 Ready | Orphan Drug for LVAD; Orphan + Fast Track in cardiorenal setting |
| VLX-1005 | IV 12-LOX inhibitor | Heparin-Induced Thrombocytopenia (HIT) | Phase 2 | Orphan + Fast Track (FDA); Orphan (EMA) |
| Frunexian | IV Factor XIa inhibitor | Device-related and procedural thrombosis | Phase 2 Ready | Two Phase 1 trials completed; China rights to Haisco |
| EP-7327 | Oral Factor XIa inhibitor | Chronic thrombosis indications | IND-Ready | Part of eXIthera acquisition package |
The overall concept is to span both chronic anticoagulation (tecarfarin, EP-7327) and acute or immune-mediated settings (frunexian, VLX-1005) with mechanisms that can be combined or sequenced depending on patient type and clinical context.
4. Tecarfarin: Lead Asset
A vitamin K antagonist built to address warfarin’s weaknesses.
Tecarfarin is an oral vitamin K antagonist designed to achieve more predictable pharmacokinetics than warfarin by shifting metabolism to a single esterase enzyme (CES2), rather than multiple CYP450 pathways. The goal is to reduce genetic variability, limit drug–drug interactions and stabilize INR control, particularly in patients with renal dysfunction or complex comorbidities.
Key Differentiators vs Warfarin
- Predictable metabolism: CES2-driven clearance reduces impact of common CYP polymorphisms
- Drug–drug interactions: Designed for a cleaner interaction profile versus traditional warfarin
- Renal function: Development strategy focuses on patients where DOACs are not appropriate
- Therapeutic control: Historical data suggest potential for improved time in therapeutic range
- Reversibility: As a VKA, can use similar reversal strategies familiar to clinicians
Abbott Collaboration
Abbott, the manufacturer of the HeartMate 3 LVAD, has partnered with Cadrenal to support development of tecarfarin in LVAD patients. The collaboration includes input on trial design, site selection and broader awareness. Having the LVAD device leader engaged is an important external validation for the LVAD indication.
Regulatory and Development Status
Phase 3 Ready
- Regulatory interactions held with FDA on pivotal study design
- Manufacturing scale-up and cGMP production completed
- Orphan Drug designation in LVAD population
- Orphan Drug + Fast Track status in severe cardiorenal setting
- Development program structured around LVAD and dialysis/ESKD segments
Tecarfarin is the asset closest to a registrational path and remains the core of the Cadrenal story. The LVAD and ESKD indications are both focused but clinically meaningful, and external validation from Abbott is a positive element.
5. VLX-1005: 12-LOX Inhibition for HIT
Mechanism-based approach to an immune-driven clotting disorder.
VLX-1005, acquired from Veralox Therapeutics in December 2025, is a highly selective inhibitor of human 12-lipoxygenase (12-LOX). Rather than simply adding another direct anticoagulant, Cadrenal is targeting the inflammatory and immune pathway that contributes to HIT pathophysiology.
The HIT Setting
HIT is a serious complication of heparin exposure, characterized by thrombocytopenia together with a high risk of venous and arterial thrombosis. Standard of care involves discontinuing heparin and switching to non-heparin anticoagulants, but these do not directly address immune platelet activation. A drug that modulates the underlying biology could potentially reduce thrombotic events and improve outcomes.
Why Target 12-LOX
12-LOX is implicated in platelet activation and inflammatory signaling. Preclinical work from Veralox has suggested that inhibiting this enzyme can modulate platelet function in a way that is relevant for HIT. Early clinical data from Phase 1 work showed tolerability in healthy volunteers, providing a base for the ongoing Phase 2 program in suspected HIT patients.
Market Opportunity
- Large number of hospitalized patients exposed to heparin each year
- Meaningful subset evaluated for HIT and confirmed cases annually
- No currently approved therapy designed around the immune mechanism
- Published estimates for the HIT treatment market vary widely, from hundreds of millions to several billions of dollars globally, depending on how the segment is defined.
Clinical and Regulatory Snapshot
Phase 2
First-in-Class
- Two Phase 1 studies in healthy volunteers completed with acceptable tolerability
- Ongoing Phase 2 study in patients with suspected HIT
- Early data referenced by the company focus on thrombotic event reduction
- Orphan Drug and Fast Track designations granted by FDA
- Orphan Drug designation granted by EMA
- Next logical step is a Phase 3 registration discussion with FDA
The deal structure with Veralox includes clinical, regulatory and commercial milestones as well as royalties, which means future success will translate into additional cash obligations for Cadrenal alongside revenue.
6. Frunexian: Factor XIa for Acute Care
Positioned for procedures and device-related thrombosis, not chronic AFib.
Frunexian is an IV Factor XIa inhibitor acquired from eXIthera in September 2025. While several large companies are pursuing oral Factor XIa inhibitors for chronic indications like atrial fibrillation, frunexian is being developed specifically as an IV agent for use in hospital settings.
Rationale for Factor XIa
Factor XIa sits upstream in the coagulation cascade. Individuals with congenital Factor XI deficiency are protected against thrombosis to some degree but usually do not experience spontaneous major bleeding, suggesting that selective inhibition may reduce thrombosis with a more favourable bleeding profile than traditional agents.
Intended Clinical Settings
- Cardiopulmonary bypass and major cardiac surgery
- Use around catheters and invasive procedures where device contact drives clot formation
- Other settings where short-acting, controllable anticoagulation is needed
Differentiation
The IV formulation and acute positioning distinguish frunexian from the oral Factor XIa programs led by larger companies. This can potentially reduce direct competitive pressure if development is focused on specialized surgical and device-driven use cases.
Development Status
Phase 2 Ready
- Two Phase 1 studies completed in healthy volunteers
- No serious safety signals reported in early-stage work cited by the company
- Pharmacokinetic profile with rapid onset and relatively quick clearance, suitable for acute use
- China rights previously partnered with Sichuan Haisco, which has completed a local Phase 1 study
- Cadrenal retains rights outside China and is eligible for royalties on Chinese sales
The acquisition also included EP-7327, an oral Factor XIa inhibitor that is at the IND-ready stage and could extend the franchise to chronic indications in the future.
The eXIthera deal involves up to approximately 15 million dollars in potential development and regulatory milestones, plus royalties on global commercialization, which will come into play if frunexian progresses successfully.
7. Financial Overview
Q3 2025 snapshot and implications for dilution risk.
R&D (Q3 2025)
$0.7M
G&A (Q3 2025)
$2.0M
Net Loss (Q3 2025)
($2.7M)
Cash and Equivalents
$3.9M
Shares Outstanding
≈2.1M
EPS (Q3 2025)
($1.31)
Capital Structure and Raises
During 2024, Cadrenal raised roughly ten million dollars through a combination of at-the-market (ATM) equity sales and warrant exercises. The company subsequently expanded its ATM facility again in 2025 to support development. With just over two million shares outstanding, the structure is very tight for a US-listed biotech, which amplifies both upside moves and drawdowns.
Runway and Dilution
With a quarterly net loss in the vicinity of 2–3 million dollars and cash of 3.9 million at the end of Q3 2025, the cash runway is limited. Unless a larger partnership or non-dilutive funding event materialises, further equity raises are likely. Anyone evaluating CVKD should factor in a material probability of dilution in the near to medium term.
8. Management Team
Core leadership and board additions.
Quang X. Pham – Chairman & CEO
Founder and chief executive of Cadrenal. Under his leadership the company moved from a single-asset story to a broader anticoagulation platform via the eXIthera and Veralox deals. He received the BioFlorida Executive of the Year award in late 2025. Company filings show a meaningful personal equity stake through direct ownership and trust holdings.
James J. Ferguson, MD – Chief Medical Officer
Cardiologist with FACC and FAHA credentials. Brings extensive experience in cardiovascular drug development and regulatory interactions. Responsible for late-stage development strategy, including planning around LVAD and ESKD trials and interface with Abbott.
Jeff Cole – Chief Operating Officer
Oversees operations, manufacturing, supply chain and intellectual property. A key figure in ensuring that cGMP manufacturing and clinical trial infrastructure are in place for tecarfarin and the newer assets acquired in 2025.
Lee Scott Golden, MD – Board Member
Joined the board in December 2025. Currently EVP and Chief Medical Officer at PTC Therapeutics, with past senior roles at companies such as Pfizer, Actelion, Eisai and Mesoblast. Adds additional cardiovascular and hematology experience at the board level.
9. Key 2026 Catalysts
Timeline of company-referenced milestones.
Cadrenal – 2026 Catalyst Calendar (Company Guidance and Public Disclosures)
Q1 2026
Expected initiation of a Phase 2 study of tecarfarin in ESKD/dialysis patients in early 2026, based on company guidance.
Q1–Q2 2026
Further regulatory feedback on the registrational path for VLX-1005 in HIT as discussions with FDA progress.
H1 2026
Updates on the tecarfarin LVAD program in collaboration with Abbott.
2026
Clarification of frunexian development strategy and potential Phase 2 start in acute-care indications.
Ongoing
Potential partnering or licensing discussions for specific geographic regions or indications.
Mar 2026
Q4 2025 and full-year 2025 financial results, including cash runway update and guidance.
10. Bull vs Bear Case
Summary of main positives and key risk factors.
Bull Case
- Three differentiated clinical assets with coherent focus on anticoagulation niches.
- Multiple Orphan and Fast Track designations that can support regulatory and commercial positioning.
- External validation through collaboration with Abbott in LVAD.
- VLX-1005 offers a mechanism-based approach to HIT, not just another direct anticoagulant.
- Frunexian and EP-7327 provide optionality in the emerging Factor XIa space.
- Very low share count creates strong sensitivity to positive clinical or partnership news.
- Analyst targets in the 30–45 dollar range imply substantial upside from current levels if the programs execute well.
- Platform structure reduces pure single-asset binary risk compared to many microcap peers.
Bear Case
- Limited cash runway based on Q3 2025 figures, making further dilution likely.
- No approved products and ongoing operating losses typical of early-stage biotech.
- Clinical risk: success in LVAD, ESKD and HIT is not guaranteed despite promising rationale.
- Competition from much larger companies in Factor XIa, at least in some segments of that space.
- Smaller patient populations make commercial execution critical and reduce margin for error.
- Complexity of running multiple programs with a relatively small team and limited resources.
- Volatility and liquidity risk, as microcaps can move sharply on relatively modest trading volumes.
- Milestone and royalty obligations to eXIthera and Veralox will reduce net economics if assets succeed.
11. Analyst Coverage and Targets
How the small group of covering analysts frame the story.
Consensus Rating
Buy / Outperform
Average Target (Zacks)
$35.67
Target Range
$30 – $45
Representative Target
$32 (HC Wainwright)
Recent Price
$7.26
Upside to Avg
≈+390%
Coverage is limited but constructive. HC Wainwright and other specialists in small-cap biotech frame CVKD as a high-risk/high-upside play on a differentiated anticoagulation platform, with the bulk of value currently assigned to tecarfarin and increasing optionality from VLX-1005 and frunexian. As always with microcap research, these targets represent a scenario-based view rather than a guarantee and should be read in the context of the company’s funding needs and execution risk.
12. Conclusion and Key Takeaways
How CVKD fits into the speculative biotech landscape.
Cadrenal has moved quickly in a short time: from a single-asset cardiorenal story to an emerging platform in complex anticoagulation niches. Tecarfarin remains the anchor asset, but the additions of frunexian and VLX-1005 mean that the company now spans three mechanisms and several related indications.
Summary of the Setup
- Focused strategy around LVAD, ESKD and HIT, where current options are unsatisfactory or limited.
- Three clinical-stage assets and one IND-ready candidate provide more than one path to value creation.
- Multiple Orphan and Fast Track designations add potential regulatory and economic benefits.
- Collaboration with Abbott in LVAD gives external validation in one of the most important indications.
- Short cash runway and small size make funding, dilution and execution the central practical risks.
From a risk perspective, CVKD sits firmly in the speculative end of the biotech spectrum. The programs are still at least one major clinical step away from registration, there is no guaranteed financing path and the share price will likely react sharply to both positive and negative news. This type of profile tends to suit traders and investors who are comfortable with binary clinical and financing events and who size positions accordingly.
For those who accept that level of risk, Cadrenal offers direct exposure to a set of anticoagulation themes that are not crowded by large-cap competitors and that are backed by targeted regulatory designations. The coming 12–24 months, with progress in LVAD, ESKD and HIT and a clearer view on frunexian, will be crucial in determining whether the platform justifies the optimistic analyst scenarios that currently exist on paper.